Last updated: April 24, 2026
What was the case and what did it target?
Celgene Corporation v. Barr Laboratories, Inc. is a U.S. federal patent infringement action filed in the District of New Jersey under docket number 2:07-cv-00286. The litigation centered on Celgene patent rights covering thalidomide-related pharmaceutical compositions and/or methods of use and Barr’s Abbreviated New Drug Application (ANDA) pathway conduct. The case aligns with Celgene’s broader enforcement portfolio around immunomodulatory drug IP tied to thalidomide derivatives and formulations, and it proceeded in the typical Hatch-Waxman structure: Celgene asserted patents listed in connection with an approved product; Barr sought approval for a competing product via ANDA and contested infringement and/or validity.
What were the procedural milestones that matter for investors?
The docket number indicates a filing year of 2007, placing the case in the first wave of U.S. Hatch-Waxman thalidomide formulation enforcement. Investors typically focus on three events in this fact pattern: (1) court rulings on claim construction, (2) rulings on infringement and invalidity (including obviousness and anticipation), and (3) settlement or termination milestones that determine generic launch timing.
However, the provided prompt does not include any docket events, orders, complaints, patents, claim terms, or the case disposition. With no case documents or dates included, a complete, accurate litigation chronology cannot be produced from the information available in this request.
What did the court likely decide on infringement and validity?
This cannot be stated accurately without:
- the specific patents asserted,
- the asserted claims,
- the alleged Barr product(s) and ANDA number(s), and
- the court’s claim construction and merits rulings.
The thalidomide-derivative patent space includes multiple Celgene families and multiple formulation/method claim styles. The litigation outcome could turn on any of:
- whether Barr’s formulation meets compositional limitations,
- whether the asserted method claims are performed by use instructions,
- whether the claims are anticipated or obvious based on prior thalidomide formulation art, or
- whether the patents are enforceable (including prosecution history estoppel or statutory defenses).
The record is not provided, so any merits characterization would risk being incorrect.
What patents and claims were at issue?
No asserted patent numbers, publication identifiers, or claim sets are provided in the prompt. A patent-level analysis requires those inputs to determine:
- which family (active compound, polymorph, formulation, dosing regimen, or method of treatment) was asserted,
- which claim limitations drive infringement (e.g., drug form, excipients, dissolution profile, dosing schedule), and
- which validity arguments were actually litigated.
Without them, the analysis cannot be completed.
How does Barr’s litigation posture typically show up in cases like this?
In Hatch-Waxman thalidomide formulation disputes, a generic defendant’s litigation posture usually includes four pillars:
- Non-infringement based on differences in composition, formulation parameters, or label-driven method performance.
- Invalidity via anticipation/obviousness based on prior art formulations and/or therapeutic use disclosures.
- Indefiniteness challenges for claim terms that depend on measurable properties (for example, ranges or functional limitations).
- Procedural defenses such as venue, standing, or timing issues, though the core disputes usually center on merits.
This is a pattern description, not a finding about Celgene v. Barr.
What is the business impact if the outcome favored Barr or Celgene?
The business impact depends entirely on the disposition. Investors need the specific outcome category:
- case dismissed on jurisdiction or pleading grounds,
- summary judgment on non-infringement,
- summary judgment on invalidity,
- trial verdict and injunction scope, or
- settlement with license terms and launch timing.
Because the disposition is not included, the injunction risk and generic launch implications cannot be tied to this specific case.
Key actionable takeaways
- The docket identifier 2:07-cv-00286 places this dispute in 2007-era Hatch-Waxman thalidomide-related patent enforcement by Celgene against Barr.
- A full litigation summary (asserted patents, claim construction, infringement/invalidity rulings, and settlement or final disposition) cannot be stated from the information provided in this request.
- For decision-grade analysis, the missing elements are not peripheral; they determine whether the case outcome supported Celgene’s enforceability position or cleared the way for Barr.
FAQs
What is the jurisdiction for 2:07-cv-00286?
It is a U.S. federal action in the District of New Jersey (based on the case caption and docket format provided).
Was this an ANDA Hatch-Waxman case?
Given the parties and typical Celgene enforcement in this period, the matter is consistent with Hatch-Waxman structure, but the prompt does not include the ANDA details required to confirm.
Which patents did Celgene assert against Barr?
The prompt does not list asserted patent numbers or publication identifiers.
Did the court issue claim construction rulings?
No claim construction details are provided in the prompt.
What was the final outcome and effect on market entry?
The prompt does not include the disposition, settlement terms, or injunction status.
Key Takeaways
- The case is Celgene v. Barr Laboratories, Inc. under 2:07-cv-00286 and falls within 2007-era thalidomide-related Hatch-Waxman patent enforcement activity.
- The prompt does not include the core record elements (asserted patents, rulings, and disposition), so a complete, accurate litigation summary and patent analysis cannot be produced.
References
[1] Docket designation: Celgene Corporation v. Barr Laboratories, Inc., 2:07-cv-00286 (D.N.J.).
